Suven Life Sciences Limited — Board Meeting, 03-07-2025: Outcome of Board Meeting

Suven Life Sciences has announced a board meeting approving the allotment of 6.4 crore convertible warrants to 23 investors, including the promoter group and various institutional and individual investors, at Rs. 134 per warrant. The company raised over Rs. 214 Cr through this preferential issue, with 25% payment received upfront. This move strengthens Suven’s capital base without immediate change to paid-up equity. The fresh funds could support growth initiatives and R&D efforts in the specialty pharma space. Keep an eye on how this capital inflow drives Suven’s next phase of expansion.